Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT: NCT06352372 · COMPLETED
Brief Summary
For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children with abnormal EEGs with epileptiform discharges or with epilepsy. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical practice of treating autism. At the beginning, at five weeks, and at the end of study, the clinician will complete the CARS-2, SRS, CGI, and a caregiver interview; additionally, questionnaires will be administered to caregivers during one of the 1-hour weekly treatment sessions.
Frequently Asked Questions
What is Safety and Efficacy of tPBM for Epileptiform Activity in Autism?
Safety and Efficacy of tPBM for Epileptiform Activity in Autism is a clinical trial registered under NCT06352372. Current status: COMPLETED.
What is the status of NCT06352372?
The current status of NCT06352372 (Safety and Efficacy of tPBM for Epileptiform Activity in Autism) is: COMPLETED.
When did Safety and Efficacy of tPBM for Epileptiform Activity in Autism start?
Safety and Efficacy of tPBM for Epileptiform Activity in Autism started on 2024-07-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.